DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Tralokinumab is an investigational drug.
There have been 10 clinical trials for Tralokinumab. The most recent clinical trial was a Phase 2 trial, which was initiated on June 19th 2018.
The most common disease conditions in clinical trials are Eczema, Dermatitis, Atopic, and Dermatitis. The leading clinical trial sponsors are LEO Pharma, Emma.Guttman, and AstraZeneca.
There are five US patents protecting this investigational drug and sixty-nine international patents.
Recent Clinical Trials for Tralokinumab
|Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis Who Are Not Adequately Controlled With or Have Contraindications to Oral Cyclosporine A||LEO Pharma||Phase 3|
|Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND||LEO Pharma||Phase 3|
|Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)||LEO Pharma||Phase 2|
Top disease conditions for Tralokinumab
Top clinical trial sponsors for Tralokinumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Tralokinumab||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|Tralokinumab||Start Trial||Cholestosome vesicles for incorporation of molecules into chylomicrons||THERASYN SENSORS, INC. (Eggertsville, NY)||Start Trial|
|Tralokinumab||Start Trial||Meditopes and meditope-binding antibodies and uses thereof||City of Hope (Duarte, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|